Summit Therapeutics (SMMT) reported first-quarter 2025 loss per share of 9 cents, narrower than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago period, the company incurred a loss of 6 cents.The reported loss included stock-based compensation expenses. Excluding these expenses, the adjusted loss per share was 7 cents, wider than the year-ago adjusted loss of 5 cents.As the company lacks any marketed product in its portfolio, it did not record quarterly revenues. (Find the latest EPS esti ...